New drug combo shows promise for Hard-to-Treat stomach cancer
Disease control
Recruiting now
This study tests whether combining two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—can help people with advanced GIST that has a specific gene change (KIT exon 17 mutation) and has stopped responding to standard treatments. About 100 adults will be r…
Phase: PHASE2 • Sponsor: Jian Li • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC